ECI1

Across TCGA pan-cancer cohorts, ECI1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ECI1 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ECI1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ECI1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ECI1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.977	0.330	.011	35	view →
HNSC	DFS	Tertile	All	1.000	0.475	.024	15	view →
LUAD	DFS	Median	III,IV	0.702	0.305	.021	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.771	1.000	.013	2	view →
LSCC	DFS	Median	All	0.861	0.461	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ECI1–PDAC (OS)

Open the PDAC breakdown →